US › Healthcare

Passage Bio Inc (PASG)

US · Healthcare · Biotechnology

$3.50-2.78%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.8M

EPS

$-2.44

EPS estimate

$-2.20

EPS came in at -2.44 against a street estimate of -2.20 — a miss of 10.9%.

Key statistics

Market cap

$14.6M

Forward P/E

0.0

P/B

3.61

Book value

$1.39

EPS (TTM)

$-11.33

52-week high

$20.00

52-week low

$3.29

50-day MA

$4.56

200-day MA

$7.03

Beta

1.39

Analyst view

Analysts rate Passage Bio Inc a buy (1 buy, 2 hold, 0 sell out of 3) with an average price target of $15.50.

Shareholding

Insiders

7.71%

Institutions

46.43%

Largest institutional holders

Fund	Stake
Lynx1 Capital Management, LP	20.94%
Vanguard Capital Management, LLC	3.54%
Balyasny Asset Management LLC	3.33%
Ikarian Capital, LLC	3.09%
Yiheng Capital LLC	2.68%
Renaissance Technologies Corp	1.49%
Erste Asset Management GmbH	1.26%
Geode Capital Management, LLC	1.15%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Passage Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.